Tafalgie Therapeutics
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.7Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2023-07-01attributed |
| Founded | unknown |
| Headquarters | Marseille, France |
| Industry | biotech |
| Stage | unknown |
| Website | tafalgie.fr |
Tafalgie Therapeutics develops non-opioid painkillers based on the endogenous protein TAFA4 that modulates pain signaling. It targets patients with acute and chronic pain, including postoperative pain. Its disease-modifying approach aims to relieve pain without tolerance or dependence.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2023-07-01 | grant | $2.7M | undisclosed |
Detected tech stack
WordPress 6.9.4, WordPress Block Editor, LiteSpeed, PHP, MySQL, jquery 3.7.1, bootstrap 3.4.2
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | tafalgie.fr, read 2026-05-08 |
| Description | self-reported | tafalgie.fr, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.